These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22025507)
1. Chelation of aluminum by combining deferasirox and deferiprone in rats. Saljooghi AS Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507 [TBL] [Abstract][Full Text] [Related]
2. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats. Amiri A; Fatemi SJ; Fatemi SN Biometals; 2007 Apr; 20(2):159-63. PubMed ID: 16927173 [TBL] [Abstract][Full Text] [Related]
3. Chelation of cadmium by combining deferasirox and deferiprone in rats. Jamilaldin Fatemi S; Saljooghi AS; Balooch FD; Iranmanesh M; Golbafan MR Toxicol Ind Health; 2011 May; 27(4):371-7. PubMed ID: 21245204 [TBL] [Abstract][Full Text] [Related]
4. Chelation of aluminium by combining DFO and L1 in rats. Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797 [TBL] [Abstract][Full Text] [Related]
5. Chelation of thallium by combining deferasirox and desferrioxamine in rats. Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432 [TBL] [Abstract][Full Text] [Related]
6. Chelation of bismuth by combining desferrioxamine and deferiprone in rats. Tubafard S; Fatemi SJ Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876 [TBL] [Abstract][Full Text] [Related]
7. Chelation of chromium(VI) by combining deferasirox and deferiprone in rats. Iranmanesh M; Fatemi SJ; Ebrahimpour R; Dahooee Balooch F Biometals; 2013 Jun; 26(3):465-71. PubMed ID: 23670101 [TBL] [Abstract][Full Text] [Related]
8. Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats. Fatemi SJ; Saljooghi AS; Balooch FD; Iranmanesh M; Golbafan MR Toxicol Ind Health; 2012 Feb; 28(1):35-41. PubMed ID: 22134990 [TBL] [Abstract][Full Text] [Related]
9. Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model. Balooch FD; Fatemi SJ; Iranmanesh M Biometals; 2014 Feb; 27(1):89-95. PubMed ID: 24309925 [TBL] [Abstract][Full Text] [Related]
10. Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats. Iranmanesh M; Fatemi SJ; Golbafan MR; Balooch FD Biometals; 2013 Oct; 26(5):783-8. PubMed ID: 23846228 [TBL] [Abstract][Full Text] [Related]
11. The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin. Moosavi-Movahedi AA; Mousavy SJ; Divsalar A; Babaahmadi A; Karimian K; Shafiee A; Kamarie M; Poursasan N; Farzami B; Riazi GH; Hakimelahi GH; Tsai FY; Ahmad F; Amani M; Saboury AA J Biomol Struct Dyn; 2009 Dec; 27(3):319-39. PubMed ID: 19795915 [TBL] [Abstract][Full Text] [Related]
12. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770 [TBL] [Abstract][Full Text] [Related]
13. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Kontoghiorghes GJ Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Bruin GJ; Faller T; Wiegand H; Schweitzer A; Nick H; Schneider J; Boernsen KO; Waldmeier F Drug Metab Dispos; 2008 Dec; 36(12):2523-38. PubMed ID: 18775980 [TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897 [TBL] [Abstract][Full Text] [Related]
17. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Ibrahim AS; Spellberg B; Edwards J Curr Opin Infect Dis; 2008 Dec; 21(6):620-5. PubMed ID: 18978530 [TBL] [Abstract][Full Text] [Related]
18. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380 [TBL] [Abstract][Full Text] [Related]
19. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Weiss HM; Fresneau M; Camenisch GP; Kretz O; Gross G Drug Metab Dispos; 2006 Jun; 34(6):971-5. PubMed ID: 16531476 [TBL] [Abstract][Full Text] [Related]
20. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]